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Abstract
Objective: To establish the reliability and validity of a shortened (10-item) depression scale used among HIV-positive
patients enrolled in the Drug Treatment Program in British Columbia, Canada.
Methods: The 10-item CES-D (Center for Epidemiologic Studies Depression Scale) was examined among 563 participants
who initiated antiretroviral therapy (ART) between August 1, 1996 and June 30, 2002. Internal consistency of the scale was
measured by Cronbach’s alpha. Using the original CES-D 20 as primary criteria, comparisons were made using the Kappa
statistic. Predictive accuracy of CES-D 10 was assessed by calculating sensitivity, specificity, positive predictive values and
negative predictive values. Factor analysis was also performed to determine if the CES-D 10 contained the same factors of
positive and negative affect found in the original development of the CES-D.
Results: The correlation between the original and the shortened scale is very high (Spearman correlation coefficient = 0.97
(P,0.001). Internal consistency reliability coefficients of the CES-D 10 were satisfactory (Cronbach a= 0.88). The CES-D 10
showed comparable accuracy to the original CES-D 20 in classifying participants with depressive symptoms (Kappa = 0.82,
P,0.001). Sensitivity of CES-D 10 was 91%; specificity was 92%; and positive predictive value was 92%. Factor analysis
demonstrates that CES-D 10 contains the same underlying factors of positive and negative affect found in the original
development of the CES-D 20.
Conclusion: The 10-item CES-D is a comparable tool to measure depressive symptoms among HIV-positive research
participants.
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Introduction
Depression is a major problem among people living with HIV/
AIDS [1,2]. The Center for Epidemiologic Studies Depression
Scale (CES-D) is one of the most common screening tests for
identifying depressive symptoms in the general population [3].
The 20-item scale is a self-reported measure of an individual’s
depressive feelings and behaviors in the past week. It is designed
for studies ascertaining the relationship between depression and
other variables. Major components of depressive symptomology
are incorporated into the scale including, depressed mood, feelings
of guilt and worthlessness, feelings of helplessness and hopeless-
ness, psychomotor retardation, loss of appetite, and sleep
disturbance [3]. The scale’s validity and reliability to detect both
clinical and non-clinical depressive symptoms have been well
established [3]. Moreover, the scale has been widely used in
different cohort studies suggesting its suitability for a variety of
sample populations and diverse contexts.
Despite the CES-D scale’s established reliability among
general populations, when embedded in large-scale surveys,
the 20-item measurement tool is lengthy and onerous. A few
studies have shown that the CES-D could be reduced to 10-
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items with comparable reliability and validity to the original
scale, though none with entire cohorts of HIV-positive
individuals [4–7]. Previous studies have used various depression
scales, such as the Hospital Anxiety and Depression Scale
(HADS) [7], the Beck Depression Inventory (BDI) [8] and the
Hamilton Rating Scale [9] to assess HIV-positive persons.
While the BDI has been validated as a shortened scale to
increase utilization, research has found that the questions in the
BDI are depressing and too focused on the body [10,11]. HIV
is a condition that spans physical, mental, emotional, social and
environmental spheres of health, thus the CES-D scale was
selected for use in our research study. The validation of the 10-
item CES-D scale may aid survey administration and reduce
interviewee burden, especially for HIV patients, many of who
are marginalized and face literacy limitations and have
competing life demands.
Depression in HIV patients is often under-identified and under-
treated which may become very harmful to HIV patients. A meta-
analysis of ten studies investigating the relationship between HIV
infection and depressive disorders found the frequency of events
was nearly two times higher in people living with HIV compared
to HIV-negative individuals [12]. Furthermore, studies have
demonstrated that the presence of depressive symptoms in HIV-
positive individuals is associated with earlier mortality and
increased HIV-specific morbidity, despite access to HAART
[1,13–16]. Specifically, depressive symptoms have been found to
be associated with key clinical markers of disease progression such
as reduced CD4 counts [14], increased activated CD8 lymphocyte
counts [17] and reduced virologic suppression for people accessing
therapy [18].
The purpose of this study is to validate the shortened 10-item
CES-D scale among a cohort of HIV-positive individuals.
Methods
Ethics Statement
Ethical approval was granted by the Providence Health Care
Research Ethics Board to use the data for research purposes.
Written consent via a standardized consent form approved by the
Research Ethics Board verified participant consent prior to any
data collection or engagement in the study. Participants who
declined to participate, before, during or after data collection or
otherwise did not participate remained eligible for treatment and
were not disadvantaged in any other way by not participating in
the study.
HIV/AIDS Drug Treatment Program
This study was conducted at the Drug Treatment Program
(DTP), at the BC Centre for Excellence in HIV/AIDS, which is
mandated by the provincial government to distribute antiretroviral
medications free of charge to all eligible HIV-positive individuals.
The DTP distributes medications in accordance with the BC
Therapeutic Guideline Committee, which have remained consis-
tent with those from the International AIDS Society-USA between
1996 and the most recent revision in 2010 [19]. Details regarding
the distribution of antiretroviral medications though the DTP have
been previously described in depth [20]. In brief, physicians enter
individuals into the DTP when they are first prescribed ART. The
enrolling physician must complete a drug request form, which acts
as a legal prescription and is used to compile baseline information
including past HIV-specific drug history, CD4 cell counts, plasma
HIV RNA levels, current drug requests, and enrolling-physician
data.
Study Subjects and Data Collection
Between August 1, 1996 and June 30, 2002, a total of 1,011
participants completed enrollment surveys, which elicited socio-
demographic, clinical and behavioral data including the 20-item
CES-D scale. Four hundred and forty-eight (44%) were excluded
because they did not complete all 20 questions on the CES-D
scale, thus 563 were included in this analysis. A comparison of the
included and excluded participants showed that, while there is no
significant age difference, the excluded group had more females,
higher median CD4 cell counts, lower viral load baseline
measurements, and fewer individuals that had completed high
school. Participants were $18 years of age and naı¨ve to
antiretroviral therapy when they started HAART.
CES-D 20 and CES-D 10
The CES-D 20 component of the survey [3] was administered
and completed by HIV-positive participants at their enrollment in
the provincial Drug Treatment Program. In brief, subjects
responded to each item of the scale by rating the frequency of
each mood or symptom ‘‘during the past week’’ on a four-point
scale. A score is assigned by totaling all items (after reversing the
positive mood items]. The possible range for the 20-item scale is 0
to 60, and a cut off score of 16 or higher indicates the presence of
significant depressive symptoms.
Our shortened scale was selected from a previously validated
ten items in an older adult population [6]. A list of all CES-D 20
items is presented in Table 1, with an asterisk identifying the ten
items of our proposed shortened scale. In accordance with
Andresen, the possible range of the 10-item scale is 0 to 30, and
a cut off score of ten or higher indicates the presence of significant
depressive symptoms.
Data Analysis
For each individual we compared their responses to the 20-item
scale to our proposed 10-items. The agreement between the CES-
D 20 and CES-D 10 was measured using the spearman correlation
coefficient and the kappa statistic with two-tailed probability for
statistical significance. Cronbach’s alpha [21] was used to estimate
the internal consistency of the items within the scale. A reliability
coefficient exceeding 0.70 was considered acceptable. Sensitivity
and specificity were calculated for the proposed CES-D 10, with
sensitivity being the probability of identifying correctly those
participants with significant depressive symptoms, while specificity
measured the probability of identifying correctly those participants
without significant depressive symptoms. Factor analysis with
varimax rotation was conducted to examine the latent structure of
the new scale. All analyses were conducted using SAS version 9.1.3
(SAS, Cary, North Carolina, United States) with a level of
significance set at 0.05.
Results
The baseline characteristics of the 563 participants have been
previously reported [1]. Within the sample, the median age was 38
years (IQR: 34–46 years) and 14% reported aboriginal ancestry, as
noted in table 2. In addition, 35% of participants had an average
annual income of less than $10,000, 29% did not complete high
school, 28% had a history of injection drug use, 20% had an AIDS
diagnosis at baseline and 23% reported suboptimal adherence
($95%) in the first year of follow-up (table 2). Clinical
characteristics included a median CD4 cell count of 230 cells/
mL (IQR: 80-390 cells/ul), and median HIV RNA plasma viral
load (pVL) of 120,000 copies/ml (IQR: 43800-280000 copies/ml)
at their initiation of antiretroviral therapy.
Shortened Depression Scale
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We initially compared participants categorized as significant vs
non-significant depressive scores on the two scales (table 2). The
Kappa statistic for the two methods was 0.82 (table 3). In detail,
289 individuals (51%) were classified as having significant
depressive symptoms (CES-D-20$16) and 284 individuals (50%)
were classified as having significant depressive symptoms (CES-D-
10$10) (see table 3). These data suggest that the brief scale is able
to identify individuals with significant depression with good
precision.
A factor analysis was conducted to reveal the internal structure
of the two scales (as seen in Table 4). Factor 1 was made up of
eight items that are all negative statements on patient’s daily life
and feeling (all with correlation.0.5) and the remaining two items
that are both positive statements were loaded heavily on factor 2
(both with correlation .0.7). The structure clearly revealed two
independent factors of the CES-D 10, which were similar to the
‘‘negative (depressed) affect’’ and ‘‘positive’’ affect of the original
version of the CES-D. The two factors together explained nearly
60% of the variation of the data.
Discussion
In our analysis, the CES-D-10 scale accurately predicts
significant depressive symptoms with good precision in compar-
ison to the 20-item scale. While the reliability of the shortened
scale in screening for depressive symptoms in healthy older adults
has been demonstrated [6], our findings extend previous reports of
the reliability of shortened scales to HIV+ populations who are
treatment-naı¨ve at time of enrollment. The factor analysis
concluded that the factors most associated with predicating
outcomes in the 20-item scale were paralleled in the 10-item
scale. The current study provides evidence that the 10-items
selected here from the original CES-D scale can be a reliable and a
valid measure of significant depressive symptoms among HIV-
positive participants.
Given the length of comprehensive questionnaires used to
survey the well-being and health of HIV-positive research
participants, a shortened scale is needed to allow for a more
rapid assessment of significant depressive symptomology, while still
maintaining a high degree of sensitivity. This shortened tool will
prove to be especially relevant when surveying populations faced
with chaotic and un-structured daily lives that may find a 20-item
scale too onerous. A number of studies demonstrate a high
prevalence of depression among HIV-positive populations and the
negative health outcomes of this co-morbidity, which again
underlines the importance of this shortened scale [12]. This tool
will improve the ability of clinical and public health researchers to
assess depressive symptoms among HIV-positive individuals.
Limitations
There are several limitations of this study. Future studies should
examine the test-retest reliability of the CES-D-10 item scale.
While we have shown the reliability of this scale using internal
consistency, measured by Cronbach’s alpha [21], unfortunately,
Table 1. Center for Epidemiologic Studies Depression Scale
(CES-D).
1) I was bothered by things that usually don’t bother me.*
2) I did not feel like eating; my appetite was poor.
3) I felt I could not shake off the blues even with the help from my family
and friends.
4) I felt that I was as good as other people.
5) I had trouble keeping my mind on what I was doing.*
6) I felt depressed.*
7) I felt that everything I did was an effort.*
8) I felt hopeful about the future.*
9) I thought my life had been a failure.
10) I felt fearful.*
11) My sleep was restless.*
12) I was happy.*
13) I talked less than usual.
14) I felt lonely.*
15) People were unfriendly.
16) I enjoyed life.
17) I had crying spells
18) I felt sad.
19) I felt that people dislike me.
20) I could not get ‘‘going’’.*
*Indicates items on our proposed CES-D-10.
doi:10.1371/journal.pone.0040793.t001
Table 2. Characteristics of sample and characteristics of participants classified by CES-D-10.
Baseline characteristics,
ALL (n=563) CES-D 10 (,10) CES-D (.=10) p-value
Age, median (Q1–Q3) 38(34–46) 39(34–46) 38(34–45) 0.207
Gender (male), n% 91% 95% 87% 0.001
CD4 cell count, (cells/ul), median(Q1–Q3 230 (80–390) 230 (110–400) 230 (75–380) 0.450
Plasma Viral Load (copies/ml), median(Q1–Q3) 120,000 (43,800–280,000) 100,010 (42,000–251,000) 131,000 (46,500–324,000) 0.036
Annual income , $10,000, n% 35% 23% 46% ,0.001
Do not complete high school, n% 29% 24% 37% ,0.001
History of injection drug use, n% 28% 20% 37% ,0.001
Aboriginal, n% 14% 14% 15$ 0.969
AIDS diagnoses, n% 20% 20% 20% 0.918
,95% adherence, n% 23% 18% 28% 0.007
doi:10.1371/journal.pone.0040793.t002
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unlike previous studies [6,7], where these authors assessed the test-
retest reliability, we were unable to assess the test-retest reliability
because these participants were not followed up with the same
instrument items. However, previous research has used the same
ten items to demonstrate that the test-retest reliability of the scale
has been satisfied [6].
Our study did not compare the CES-D 10 with clinical
diagnoses of depression made by licensed psychiatrists, as the BC-
CfE does not collect or link to this data. Although the original
CES-D was not designed as a clinical diagnostic tool, the shorter
instrument may still benefit from comparisons with clinical criteria
of depression, such as the Research Diagnostic Criteria (RDC) or
the Diagnostic Interview Survey (DIS).
With a potential sample size of 1,011 for this analysis, nearly
half (44%) were excluded because they failed to complete the
entire 20-question CES-D scale. Participants that did not complete
the entire scale were more likely to be female, have a higher
median CD4 cell count, lower viral load baseline measurements
and to have not completed high school. Factors such as gender,
viral load and education are also found to differ significantly
between those characterized by depressive symptoms in our study.
The authors hypothesize that individuals may have felt these
questions were irrelevant as their physical health is considered to
be satisfactory. Another reasoning for this trend is that these are
populations that are socially marginalized and have competing
priorities that don’t allow for mental health to be a concern,
suggesting that a large proportion of the population is being
overlooked in terms of their potential depressive symptoms.
Conclusion
Our analysis of the shortened 10-item CES-D scale attained
satisfactory prediction accuracy and reliability in assessing
significant depressive symptoms among HIV-positive patients.
The validation of this shortened scale provides a useful tool for
researching depressive symptomology among HIV-positive popu-
lations. We further recommend that our 10-item scale be validated
among other populations.
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